More news on SmithKline Beecham's Kytril
The results of a recent study published in February's Journal of Clinical Oncology shows that a single oral dose of the antiemetic Kytril is as effective as intravenous ondansetron in preventing chemotherapy-induced nausea and vomiting.
With nausea and vomiting being the most common side effects of chemotherapy, Kytril tablets exhibited comparable efficacy to intravenous ondansetron. Over 24 and 48 hours respectively, Kytril tablets achieved total control (no nausea, no emesis, or need for rescue antiemetic therapy) in 59% and 47% of patients, respectively, compared with 58% and 44% for intravenous ondansetron.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content